Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T21:53:30.247Z.
Calculation as of: 2026-10-06T21:53:30.247Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: efd168c3f67c3bcd8ce1d079285ce9769a1647edc12b2aee6a2fbd6fb78d637d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
First Tracks Biotherapeutics Inc
Market Cap
$1.10B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.09B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.10B
EV/EBITDA Ratio
22.47x
TTM Avg
239.72x
3Y Avg
94.93x
5Y Avg
89.53x
Market Cap
$1.08B
EV/EBITDA Ratio
34.85x
TTM Avg
40.48x
3Y Avg
32.62x
5Y Avg
34.28x
Market Cap
$1.11B
EV/EBITDA Ratio
N/A
TTM Avg
279.36x
3Y Avg
538.48x
5Y Avg
538.48x
Market Cap
$1.13B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.13B
EV/EBITDA Ratio
N/A
TTM Avg
44.15x
3Y Avg
171.76x
5Y Avg
154.47x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| First Tracks Biotherapeutics Inc (TRAX) | $1.10B | N/A | N/A | N/A | N/A |
| OPKO Health, Inc. (OPK)vs › | $1.09B | N/A | 14.49x | 15.52x | 61.39x |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.09B | N/A | N/A | N/A | N/A |
| STAAR Surgical Company (STAA)vs › | $1.10B | 22.47x | 239.72x | 94.93x | 89.53x |
| IRadimed Corporation (IRMD)vs › | $1.08B | 34.85x | 40.48x | 32.62x | 34.28x |
| Tandem Diabetes Care, Inc. (TNDM)vs › | $1.11B | N/A | 279.36x | 538.48x | 538.48x |
| Replimune Group, Inc. (REPL)vs › | $1.11B | N/A | N/A | N/A | N/A |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.13B | N/A | N/A | N/A | N/A |
| Harrow Health, Inc. (HROW)vs › | $1.13B | N/A | 44.15x | 171.76x | 154.47x |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.13B | 8.14x | 7.52x | 19.65x | 29.89x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
